ArticleCureus2025
A Technical Report for Definitive Treatment of Uveal Melanoma With Stereotactic Radiosurgery and Retrobulbar Anesthesia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma (UM) is the most common primary intraocular malignancy, traditionally managed with episcleral plaque brachytherapy or enucleation. Single-fraction stereotactic radiosurgery (SRS) using a linear accelerator (LINAC) is an emerging alternative offering high precision and eye preservation. However, existing SRS/stereotactic radiation therapy (SRT) techniques often rely on mechanical immobilization or patient-maintained fixation. To the best of our knowledge, this is the first report of single-fraction, LINAC-based, frameless robotic SRS with retro- and peribulbar anesthesia for ocular immobilization from the United States. Additionally, we review the literature to assess local control, enucleation rates, and treatment-related toxicity of SRS/SRT for UM. Patients diagnosed with UM at our institution were evaluated by a multidisciplinary team of radiation oncologists and ophthalmologists. A thermoplastic mask and retro- and peribulbar anesthesia were used for ocular immobilization. Treatment planning involved computed tomography (CT) and magnetic resonance imaging (MRI) fusion for target delineation. Gross tumor volume (GTV) encompassed the entire tumor, with a 2 mm planning target volume (PTV) expansion and no clinical target volume (CTV). Treatment was delivered using the CyberKnife® system (Accuray Incorporated, Sunnyvale, California, United States) in a single 20 Gy fraction at the 80% isodose line, with real-time imaging for precise radiation delivery. Patients were monitored post-treatment for acute complications, with follow-up assessments of local tumor control, eye retention, and treatment-related toxicity. Additionally, we conducted a literature review of SRS/SRT studies, collecting data on patient numbers, tumor size, radiation regimens, immobilization techniques, and clinical outcomes, including local control, complications, and eye retention rates. This study demonstrates the feasibility of single-fraction, frameless LINAC-based SRS using CyberKnife with retro- and peribulbar anesthesia as an effective, patient-friendly alternative for treating UM. Patients with medium to large tumors are excellent candidates, even with a single 20 Gy fraction. This technique eliminates the need for mechanical eye immobilization while maintaining tumor control rates comparable to established modalities with potentially improved patient comfort. We aim to further evaluate our cohort's long-term patient outcomes, including local control, vision preservation, and late toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.